Skip to content

Study · Non-randomized trial · n = 12 · 1998

5 results

Does desensitization to hexarelin occur?

Rahim A, Shalet SM

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society1 Apr 1998

PMID10990150 (opens in a new tab)DOI10.1016/s1096-6374(98)80039-7 (opens in a new tab)PepBankPUB-10990150
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy elderly individuals, the GH response to twice-daily hexarelin changed significantly over 16 weeks (P = 0.0003).

    In plain wordsIn healthy older adults, the growth hormone response to twice-daily hexarelin changed over 16 weeks.

    Peptide
    Hexarelin
    Outcome
    DecreaseAUCGH change over 16 weeks
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    twice-daily injections · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    The mean (+/- SEM) areas under the GH curve (AUCGH) at weeks 0, 1, 4 and 16 were 19.1 +/- 2.4, 13.1 +/- 2.3, 12.3 +/- 2.4 and 10.5 +/- 1.8 microg/l/hour, respectively. There was a significant change in AUCGH over the study period (P = 0.0003).
    1 context sentence
    Summary · context
    The effect of twice-daily subcutaneous injections of hexarelin on GH release was therefore investigated over a period of 16 weeks in 12 healthy elderly individuals.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy elderly individuals, the GH response to hexarelin was lower at week 4 than at baseline (P < 0.05).

    In plain wordsIn healthy older adults, the growth hormone response to hexarelin was smaller at week 4 than at the start.

    Peptide
    Hexarelin
    Outcome
    DecreaseAUCGH at week 4 versus baseline
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    twice-daily injections · subcutaneous · 16 weeksAs given in this study (human).

    Measurements

    AUCGH
    12.3 microg/l/hour
    week 4
    AUCGH
    19.1 microg/l/hour
    week 0

    Source sentences

    Summary
    Further analysis showed that the decreases in AUCGH at weeks 4 and 16 were significant (P < 0.05 and P < 0.01, respectively) compared with baseline values.
    2 context sentences
    Summary · context
    The mean (+/- SEM) areas under the GH curve (AUCGH) at weeks 0, 1, 4 and 16 were 19.1 +/- 2.4, 13.1 +/- 2.3, 12.3 +/- 2.4 and 10.5 +/- 1.8 microg/l/hour, respectively.
    Summary · context
    The effect of twice-daily subcutaneous injections of hexarelin on GH release was therefore investigated over a period of 16 weeks in 12 healthy elderly individuals.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy elderly individuals, the GH response to hexarelin was lower at week 16 than at baseline (P < 0.01).

    In plain wordsIn healthy older adults, the growth hormone response to hexarelin was smaller at week 16 than at the start.

    Peptide
    Hexarelin
    Outcome
    DecreaseAUCGH at week 16 versus baseline
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    twice-daily injections · subcutaneous · 16 weeksAs given in this study (human).

    Measurements

    AUCGH
    10.5 microg/l/hour
    week 16
    AUCGH
    19.1 microg/l/hour
    week 0

    Source sentences

    Summary
    Further analysis showed that the decreases in AUCGH at weeks 4 and 16 were significant (P < 0.05 and P < 0.01, respectively) compared with baseline values.
    2 context sentences
    Summary · context
    The mean (+/- SEM) areas under the GH curve (AUCGH) at weeks 0, 1, 4 and 16 were 19.1 +/- 2.4, 13.1 +/- 2.3, 12.3 +/- 2.4 and 10.5 +/- 1.8 microg/l/hour, respectively.
    Summary · context
    The effect of twice-daily subcutaneous injections of hexarelin on GH release was therefore investigated over a period of 16 weeks in 12 healthy elderly individuals.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy elderly individuals, re-administration of hexarelin 4 weeks after the study period increased the GH response compared with week 16 (P < 0.05).

    In plain wordsIn healthy older adults, the growth hormone response to hexarelin recovered after a four-week break.

    Peptide
    Hexarelin
    Outcome
    IncreaseAUCGH after re-administration versus week 16
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    twice-daily injections · subcutaneousAs given in this study (human).

    Measurements

    AUCGH
    19.4 microg/l/hour
    re-administration
    AUCGH
    10.5 microg/l/hour
    week 16

    Source sentences

    Summary
    Four weeks after completion of the 16-week study period, hexarelin was again administered. On this occasion, AUCGH increased significantly compared with that at week 16 (from 10.5 +/- 1.8 to 19.4 +/- 3.7 microg/l/hour; P < 0.05) and was not significantly different compared with that at week 0.
    1 context sentence
    Summary · context
    The effect of twice-daily subcutaneous injections of hexarelin on GH release was therefore investigated over a period of 16 weeks in 12 healthy elderly individuals.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy elderly individuals, the GH response after re-administration of hexarelin was not significantly different from that at week 0.

    In plain wordsIn healthy older adults, after a four-week break the growth hormone response to hexarelin was similar to the response at the start.

    Peptide
    Hexarelin
    Outcome
    No significant changeAUCGH after re-administration versus week 0
    Study

    n = 12

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    twice-daily injections · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    was not significantly different compared with that at week 0.
    2 context sentences
    Summary · context
    Four weeks after completion of the 16-week study period, hexarelin was again administered.
    Summary · context
    The effect of twice-daily subcutaneous injections of hexarelin on GH release was therefore investigated over a period of 16 weeks in 12 healthy elderly individuals.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.